Search research articles
Contact Us
Filters
Showing results (31-40 of 132) with videos related to
Page
of 14
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 3, 2008
A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies
David A Rizzieri, Eric Feldman, John F Dipersio, et al.
Archives of Pathology & Laboratory Medicine
|
November 9, 2006
Morphologic examination of sequential bone marrow biopsies after nonmyeloablative stem cell transplantation complements molecular studies of donor engraftment
Anand S Lagoo, Jerald Z Gong, Timothy T Stenzel, et al.
The American Journal of Surgical Pathology
|
May 29, 2004
Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation
Matthew J Snyder, Timothy T Stenzel, Patrick J Buckley, et al.
Leukemia Research
|
October 11, 2012
Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia
Tod A Morris, Carlos M DeCastro, Louis F Diehl, et al.
Leukemia & Lymphoma
|
April 10, 2009
Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival
Thomas C Shea, Anne W Beaven, Dominic T Moore, et al.
Blood Cancer Journal
|
August 2, 2018
Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
Dharshan Sivaraj, Michael M Green, Yubin Kang, et al.
Cancer
|
January 5, 2026
Hematopoietic effects of tagraxofusp in treatment-naive patients with blastic plasmacytoid dendritic cell neoplasm
Marina Konopleva, Naveen Pemmaraju, Kendra L Sweet, et al.
Cancer
|
May 2, 2021
A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia
Gautam Borthakur, Olatoyosi Odenike, Ibrahim Aldoss, et al.
Leukemia & Lymphoma
|
March 11, 2025
Efficacy of first-line tagraxofusp in blastic plasmacytoid dendritic cell neoplasm with prior or concomitant hematologic malignancy: subgroup analysis of a pivotal trial
Naveen Pemmaraju, Marina Konopleva, Kendra L Sweet, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
November 26, 2013
Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies
Junya Kanda, Gwynn D Long, Cristina Gasparetto, et al.
Page
of 14
Search research articles
Search
Showing results (31-40 of 132) with videos related to
Sort By:
Page
of 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 3, 2008
A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies
David A Rizzieri, Eric Feldman, John F Dipersio, et al.
Archives of Pathology & Laboratory Medicine
|
November 9, 2006
Morphologic examination of sequential bone marrow biopsies after nonmyeloablative stem cell transplantation complements molecular studies of donor engraftment
Anand S Lagoo, Jerald Z Gong, Timothy T Stenzel, et al.
The American Journal of Surgical Pathology
|
May 29, 2004
Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation
Matthew J Snyder, Timothy T Stenzel, Patrick J Buckley, et al.
Leukemia Research
|
October 11, 2012
Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia
Tod A Morris, Carlos M DeCastro, Louis F Diehl, et al.
Leukemia & Lymphoma
|
April 10, 2009
Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival
Thomas C Shea, Anne W Beaven, Dominic T Moore, et al.
Blood Cancer Journal
|
August 2, 2018
Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
Dharshan Sivaraj, Michael M Green, Yubin Kang, et al.
Cancer
|
January 5, 2026
Hematopoietic effects of tagraxofusp in treatment-naive patients with blastic plasmacytoid dendritic cell neoplasm
Marina Konopleva, Naveen Pemmaraju, Kendra L Sweet, et al.
Cancer
|
May 2, 2021
A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia
Gautam Borthakur, Olatoyosi Odenike, Ibrahim Aldoss, et al.
Leukemia & Lymphoma
|
March 11, 2025
Efficacy of first-line tagraxofusp in blastic plasmacytoid dendritic cell neoplasm with prior or concomitant hematologic malignancy: subgroup analysis of a pivotal trial
Naveen Pemmaraju, Marina Konopleva, Kendra L Sweet, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
November 26, 2013
Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies
Junya Kanda, Gwynn D Long, Cristina Gasparetto, et al.
Page
of 14